Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa.

doi:10.1016/j.semarthrit.2026.153062

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa.

Seminars in arthritis and rheumatism - 1 Oct 2026

Cabanillas-Paredes Montserrat, Calvet Joan, Almirall Miriam, Espartal Esther, Alascio Lucia, Azuaga Ana Belen, Laiz Ana, Sainz Luis, Costa Ester, Clavaguera Teresa, Juan Mas Antonio, Pujol Manel, Garbayo-Salmons Patricia, Saus Ester, Rodrigo-Parés Albert, Carreras Anna, Feliu-Hernàndez Clara, Gratacós Jordi, Arévalo-Salaet Marta, Llop Maria, Bou Nuria, Moreno Mireia

Abstract excerpt

OBJECTIVE: To characterize the clinical phenotype and disease burden in patients with concomitant spondyloarthritis (SpA) and hidradenitis suppurativa (HS) versus patients with SpA alone. METHODS: We conducted a multicenter, retrospective and matched case-control study. Cases were adults with SpA and dermatologist‑confirmed HS; controls had SpA without HS. Data from the preceding three years were extracted from...

Read the complete abstract on PubMed

Topics

Adult
Female
Humans
Male
Middle Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Case-Control Studies

Comorbidity

Cost of Illness

Hidradenitis Suppurativa

Phenotype

Retrospective Studies

Spondylarthritis

Source

Open in PubMed

Identifiers

PMID: 42664532
DOI: 10.1016/j.semarthrit.2026.153062

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa.PMID 42664532Read ↗

PAPASH , Ps APASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimensSemantic proximity Read ↗

What is peripheral spondyloarthritis? Identifying proportion, phenotype and burden in post hoc analysis of the ASAS-PerSpA study.Semantic proximity Read ↗

Pathophysiology of axial spondyloarthritis: Consensus and controversies.Semantic proximity Read ↗

Comparison of the ASAS Health Index in patients classified as radiographic axial spondyloarthritis (axSpA) or non-radiographic axSpA in the ASAS Health Index international validation study.Semantic proximity Read ↗

Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic.Semantic proximity Read ↗

Spondyloarthritis: from unifying concepts to improved treatmentSemantic proximity Read ↗

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumabSemantic proximity Read ↗

Unveiling a spondyloarthritis-like phenotype in Sjögren's disease : clinical, serological, and radiological correlates of sacroiliitis in a real-world cohort.Semantic proximity Read ↗

Recent advances in ankylosing spondylitis: understanding the disease and managementSemantic proximity Read ↗

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review.Semantic proximity Read ↗

Leveraging genotypes and phenotypes to implement precision medicine in hidradenitis suppurativa management.Semantic proximity Read ↗

Belgian Patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be): Data, Scores, and Phenotypes since 2015.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.